Department of Otology and Laryngology, Harvard Medical School, Boston, MA, USA.
Otolaryngol Head Neck Surg. 2010 Jan;142(1):108-14. doi: 10.1016/j.otohns.2009.10.007.
To reclassify facial nerve hemangiomas in the context of presently accepted vascular lesion nomenclature by examining histology and immunohistochemical markers.
Cohort analysis of patients diagnosed with a facial nerve hemangioma between 1990 and 2008.
Collaborative analysis at a specialty hospital and a major academic hospital.
Seven subjects were identified on composite review of office charts, a pathology database spanning both institutions, and an encrypted patient registry. Clinical data were compiled, and hematoxylin-eosin-stained specimens were reviewed. For six patients, archived pathological tissue was available for immunohistochemical evaluation of markers specific for infantile hemangioma (glucose transporter protein isoform 1 [GLUT1] and Lewis Y antigen) and for lymphatic endothelial cells (podoplanin).
All patients clinically presented with slowly progressive facial weakness at a mean age of 45 years without prior symptomatology. Hemotoxylin-eosin-stained histopathological slides showed irregularly shaped, dilated lesional vessels with flattened endothelial cells, scant smooth muscle, and no internal elastic lamina. Both podoplanin staining for lymphatic endothelial cells and GLUT1 and LewisY antigen staining for infantile hemangioma endothelial cells were negative in lesional vessels in all specimens for which immunohistochemical analysis was performed.
Lesions of the geniculate ganglion historically referred to as "hemangiomas" do not demonstrate clinical, histopathological, or immunohistochemical features consistent with a benign vascular tumor, but instead are consistent with venous malformation. We propose that these lesions be classified as "venous vascular malformations of the facial nerve." This nomenclature should more accurately predict clinical behavior and guide therapeutic interventions.
通过检查组织病理学和免疫组织化学标志物,重新分类目前公认的血管病变命名法中的面神经血管瘤。
1990 年至 2008 年间诊断为面神经血管瘤的患者的队列分析。
专科医院和一所主要学术医院的合作分析。
通过对两个机构的办公室图表、病理学数据库和加密患者注册表的综合审查,确定了 7 名患者。收集临床数据,并对苏木精-伊红染色标本进行了回顾。对于 6 名患者,可获得存档的病理组织,用于免疫组织化学评估特定于婴儿血管瘤的标志物(葡萄糖转运蛋白同工型 1 [GLUT1]和 Lewis Y 抗原)和淋巴管内皮细胞(足突蛋白)。
所有患者均以 45 岁的平均年龄出现进行性面神经无力,无前期症状。苏木精-伊红染色的组织病理学切片显示不规则形状的扩张病变血管,内皮细胞扁平,平滑肌稀少,无内弹性膜。所有进行免疫组织化学分析的标本中,病变血管均未显示足突蛋白(淋巴管内皮细胞标志物)染色和 GLUT1 及 Lewis Y 抗原(婴儿血管瘤内皮细胞标志物)染色阳性。
既往称为“血管瘤”的膝状神经节病变不具有与良性血管肿瘤一致的临床、组织病理学或免疫组织化学特征,而是与静脉畸形一致。我们建议将这些病变归类为“面神经的静脉血管畸形”。这种命名法应更准确地预测临床行为并指导治疗干预。